1
Cary L Queen, Man Sung Co, William P Schneider, Nicholas F Landolfi, Kathleen L Coelingh, Harold E Selick: Humanized immunoglobulins. Protein Design Labs, Townsend & Townsend & Crew, December 2, 1997: US05693762 (1197 worldwide citation)

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immuno ...


2
Man Sung Co, David A Scheinberg, Cary L Queen: Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region. Protein Design Labs, Sloan Kettering Cancer Center, Townsend and Townsend and Crew, February 3, 1998: US05714350 (203 worldwide citation)

The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region a ...


3
Man Sung Co, David A Scheinberg, Cary L Queen: Antibodies with increased binding affinity. Protein Design Labs, Memorial Sloan Kettering Cancer Center, Townsend & Townsend & Crew, February 26, 2002: US06350861 (176 worldwide citation)

The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region a ...


4
Man Sung Co, David A Scheinberg, Cary L Queen: Increasing antibody affinity by altering glycosylation of immunoglobulin variable region. Protein Design Labs, Memorial Sloan Kettering Cancer Center, Townsend and Townsend and Crew, August 23, 2005: US06933368 (85 worldwide citation)

The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region a ...


5
Man Sung Co, J Yun Tso: Humanized antibodies reactive with GPIIB/IIIA. Protein Design Labs, Townsend & Townsend & Crew, July 7, 1998: US05777085 (74 worldwide citation)

Humanized immunoglobulins specifically reactive with GPIIb/IIIa proteins are prepared employing recombinant DNA technology for use in, e.g., treatment of various thrombosis-related disorders.


6
Man Sung Co: Humanized antibodies reactive with L-selectin. Protein Design Labs, Townsend & Townsend & Crew, April 3, 2001: US06210671 (74 worldwide citation)

Humanized immunoglobulins specifically reactive with L-selectin are prepared employing recombinant DNA technology for use in e.g., treatment of inflammatory disorders.


7
Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S Gray, Andrea Knight, Denise O Hara, Bonita Rup, Geertruida M Veldman: Method of transplanting cells by contacting donor cells with B7-1-and B7-2-specific immunoglobulins. Genetics Institute, Finnegan Henderson Farabow Garrett & Dunner, January 10, 2006: US06984383 (24 worldwide citation)

The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders a ...


8
Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S Gray, Andrea Knight, Denise O Hara, Bonita Rup, Geertruida M Veldman: Humanized immunoglobulin reactive with B7 therewith. Finnegan Henderson Farabow Garrett & Dunner, July 5, 2005: US06913747 (15 worldwide citation)

The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, i ...


9

10
Kamon Shirakawa, Tomokazu Matsusue, Shigekazu Nagata, Man Sung Co, Maximiliano Vasquez: Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody. Mochida Pharmaceutical, Osaka Bioscience Institute, Birch Stewart Kolasch & Birch, September 5, 2000: US06114507 (11 worldwide citation)

An anti-Fas ligand antibody capable of suppressing Fas ligand-induced apoptosis to a high degree, especially humanized antibodies having less antigenecity to human, and a method for assaying the Fas ligand in human body fluid utilizing such an antibody.